Get started
Lyra Therapeutics, Inc.Lyra Therapeutics, Inc.Lyra Therapeutics, Inc.

Lyra Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

LYRA chart


Full chart

LYRA upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪13.85 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−60.71 USD
Net income (FY)
‪−93.44 M‬ USD
Revenue (FY)
‪1.53 M‬ USD
Shares float
‪1.33 M‬
Beta (1Y)
3.56

Employees


Employees (FY)
30
Change (1Y)
−58 −65.91%
Revenue / Employee (1Y)
‪51.13 K‬ USD
Net income / Employee (1Y)
‪−3.11 M‬ USD

About Lyra Therapeutics, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Maria Palasis
Website
lyratherapeutics.com
Headquarters
Watertown
Founded
2005
FIGI
BBG001J2N202
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. It develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases. The firms proprietary XTreo deliver medicines. The company was founded by Carmichael S. Roberts, George M. Whitesides, and Robert S. Langer in November 2005 and is headquartered in Watertown, MA.

Check out other big names from the same industry as LYRA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

LYRA news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of LYRA is 12.86 USD — it has increased by 9.95% in the past 24 hours. Watch Lyra Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Lyra Therapeutics, Inc. stocks are traded under the ticker LYRA.
LYRA stock has risen by 2.77% compared to the previous week, the month change is a 155.33% rise, over the last year Lyra Therapeutics, Inc. has showed a −6.06% decrease.
We've gathered analysts' opinions on Lyra Therapeutics, Inc. future price: according to them, LYRA price has a max estimate of 30.00 USD and a min estimate of 16.00 USD. Watch LYRA chart and read a more detailed Lyra Therapeutics, Inc. stock forecast: see what analysts think of Lyra Therapeutics, Inc. and suggest that you do with its stocks.
LYRA reached its all-time high on May 1, 2020 with the price of 1,100.00 USD, and its all-time low was 3.81 USD and was reached on May 28, 2025. View more price dynamics on LYRA chart.
See other stocks reaching their highest and lowest prices.
LYRA stock is 16.26% volatile and has beta coefficient of 3.56. Track Lyra Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Lyra Therapeutics, Inc. there?
Today Lyra Therapeutics, Inc. has the market capitalization of ‪15.23 M‬, it has decreased by −9.87% over the last week.
Yes, you can track Lyra Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Lyra Therapeutics, Inc. is going to release the next earnings report on Aug 12, 2025. Keep track of upcoming events with our Earnings Calendar.
LYRA earnings for the last quarter are −6.50 USD per share, whereas the estimation was −7.50 USD resulting in a 13.33% surprise. The estimated earnings for the next quarter are −6.02 USD per share. See more details about Lyra Therapeutics, Inc. earnings.
Lyra Therapeutics, Inc. revenue for the last quarter amounts to ‪183.00 K‬ USD, despite the estimated figure of ‪240.00 K‬ USD. In the next quarter, revenue is expected to reach ‪228.33 K‬ USD.
LYRA net income for the last quarter is ‪−8.55 M‬ USD, while the quarter before that showed ‪−10.98 M‬ USD of net income which accounts for 22.15% change. Track more Lyra Therapeutics, Inc. financial stats to get the full picture.
No, LYRA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 25, 2025, the company has 30 employees. See our rating of the largest employees — is Lyra Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Lyra Therapeutics, Inc. EBITDA is ‪−44.70 M‬ USD, and current EBITDA margin is ‪−3.93 K‬%. See more stats in Lyra Therapeutics, Inc. financial statements.
Like other stocks, LYRA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Lyra Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Lyra Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Lyra Therapeutics, Inc. stock shows the sell signal. See more of Lyra Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.